One of these molecules is the MET × EGFR bispecific antibody JNJ-61186372, jointly developed by Genmab and Janssen, currently in Phase I, for the treatment of advanced NSCLC, that was screened from five anti-MET × 8 anti-EGFR parental antibodies in the DuoBody format [33]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.